Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06221423 | Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | withdrawn | — | 0 | Fudan UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06290765 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera(PV) | withdrawn | Phase 4 | 0 | PharmaEssentiaINDUSTRY | 0 | Jul 31, 2026 | clinicaltrials |
| NCT04364672 | Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT04419909 | Retreatment With CTL019/CTL119 | withdrawn | Phase 1 | 0 | University of PennsylvaniaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07449481 | A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors | withdrawn | Phase 2 | 0 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07614828 | Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Malignant Melanoma of Nasal and Paranasal Mucosa | withdrawn | Phase 2 | 0 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03946423 | BAriaTric Surgery After Breast Cancer Treatment (BATS) | withdrawn | N/A | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT04568304 | A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma | withdrawn | Phase 3 | 0 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07693374 | Chinese Medicinal Component Relieves CIPN and Mitochondria Function | withdrawn | N/A | 0 | Taiwan Municipal An-Nan Hospital-China Medical UniversityOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT02432378 | Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07084584 | ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Galecto Biotech ABINDUSTRY | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07369791 | Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.(NOBLE) | withdrawn | Phase 2 | 0 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04273555 | Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06455189 | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT00006344 | Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer | withdrawn | Phase 3 | 0 | Virginia Commonwealth UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05578274 | Abscopal Effect From Low-dose Radiotherapy in Metastatic Cancer Combined With Stereotactic Body Radiotherapy | withdrawn | N/A | 0 | Soonchunhyang University HospitalOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Ankyra Therapeutics, IncINDUSTRY | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05416554 | Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford | withdrawn | N/A | 0 | Stanford UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03353428 | Intervention of Engineered Immune Effector T Cells Against Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07428369 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)(LINKER-MM8) | withdrawn | Phase 2 / Phase 3 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT02903277 | National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent | withdrawn | — | 0 | Centre Hospitalier Universitaire de NiceOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07136571 | Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable Hypervascular Pediatric Soft Tissue Sarcomas | withdrawn | N/A | 0 | University of Alabama at BirminghamOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT05991752 | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a Prospective Multicenter Randomized Trial(ROMECO) | withdrawn | N/A | 0 | University Hospital, ToursOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 2 | Jun 10, 2026 | clinicaltrials |
| NCT06348147 | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07292285 | The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.(SNOWW) | withdrawn | — | 0 | University of Colorado, DenverOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT05218408 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type(CYNK001GBM02) | withdrawn | Phase 1 / Phase 2 | 0 | Celularity IncorporatedINDUSTRY | 0 | Jun 8, 2026 | clinicaltrials |
| NCT05331040 | Radiomics in Rectal Cancer | withdrawn | — | 0 | NHS GrampianOTHER_GOV | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06185478 | Prostate Diffusion Imaging With Distortion Correction | withdrawn | N/A | 0 | Norfolk and Norwich University Hospitals NHS Foundation TrustOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01451853 | SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss | withdrawn | Phase 2 | 0 | Sound Pharmaceuticals, IncorporatedINDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05312476 | Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624578 | Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas - A Prospective, Multicentre, Open-label Study(REIN-TEP PSMA) | withdrawn | N/A | 0 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT03402880 | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04016818 | Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution | withdrawn | Early Phase 1 | 0 | Stanford UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06682013 | Virtual Agent Feasibility in Oncology Patients (NTT Data) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07413510 | Precision Nursing vs Conventional Care in Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Trial | withdrawn | N/A | 0 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07123662 | γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant | withdrawn | Early Phase 1 | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | May 28, 2026 | clinicaltrials |
| NCT07152210 | Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer | withdrawn | N/A | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07195617 | Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment(r/r MM) | withdrawn | N/A | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | May 28, 2026 | clinicaltrials |
| NCT05714826 | Comprehensive Optimization At-time of Radical Cystectomy Intervention(COARC) | withdrawn | N/A | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT05454163 | Post-radiotherapy Rhinosinusitis in Children(PRRSC) | withdrawn | — | 0 | University Hospital, LilleOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT04488224 | Nano-X Image Guidance: CBCT With Gravity-induced Motion(Nano-X IG) | withdrawn | Early Phase 1 | 0 | University of SydneyOTHER | 0 | May 19, 2026 | clinicaltrials |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | May 19, 2026 | clinicaltrials |
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides(Resimmune®) | withdrawn | Phase 2 | 0 | Virogen Biotechnology Inc.INDUSTRY | 0 | May 18, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 3, 2026source: clinicaltrials